Amakem, a Belgian clinical stage ophthalmology company, has appointed Kieran Rooney as Vice President of Business Development.
Rooney brings to Amakem more than 25 years of experience in the biotechnology and pharmaceutical industries and a track record in business development, commercial management and strategic consulting. As Founder and Managing Director of Halo BioConsulting, he has worked extensively in the ophthalmology space, supporting companies in both Europe and the US on transactions and commercial strategy.
Rooney was previously a consultant to the UK Government, focusing on the provision of commercial consulting, business development and global dealmaking services to UK-based life sciences companies. Prior to this, he held Business Development Director roles at companies including Smith & Nephew, F2G, Pharsight Corporation, and MDS Pharma Services.
Amakem’s leading candidate, AMA0076, is for glaucoma and entered Phase IIa development late last year. The company is also working to apply the Localised Drug Action approach to a range of other eye diseases.
